Industry News
Biotechnology Industry News
Electra Therapeutics is…
Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate.
With $70 million and a phase 2…
With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the treatment of rheumatoid arthritis.
“We need to pick a lane here as…
“We need to pick a lane here as a country. Which one do we care more about? Proving survival, which means no crossover; or getting U.S. participation, where crossover is a pretty important incentive,” Eli
GSK and Spero Therapeutics have…
GSK and Spero Therapeutics have shared phase 3 results on their antibiotic candidate, revealing that the oral therapy closely matched the intravenous incumbent in a trial that could support filings for approval.
Neuphoria Therapeutics’ lead…
Neuphoria Therapeutics’ lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the biotech to discontinue the program and launch a strategic review of its business.
Galapagos is planning to wind down…
Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months.
After rejecting Replimune’s…
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval application.
The U.S. private equity market is…
The U.S. private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving optimism, though exit and fundraising challenges remain.
As scientific disinformation…
As scientific disinformation skyrockets, the Biotechnology Innovation Organization (BIO)—the world’s largest biotech trade association—is aiming to set the record straight on vaccines, rolling out a campaign highlighting the unmistakable value immunizations have on public health
BioNTech is not planning further…
BioNTech is not planning further trials of its BNT111 vaccine candidate in a specific late-stage refractory melanoma setting, a company spokesperson said.
Daiichi Sankyo and Merck & Co….
Daiichi Sankyo and Merck & Co. have reported midphase ovarian cancer data, clearing the partners to advance the antibody-drug conjugate into the phase 3 part of the trial.
Roche is forging ahead with plans…
Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials.
From Roche’s $1.4 billion…
From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates (ADCs) dominated Europe’s leading cancer conference over the weekend.
The company believes the data for…
The company believes the data for zanzalintinib validate its hopes of having another “franchise molecule” on its hands.
Moderna’s efforts to advance its…
Moderna’s efforts to advance its cancer pipeline “make sense” against the backdrop of a more skeptical U.S. government attitude to infectious disease vaccines, the company’s oncology chief told Fierce.
Europe’s leading cancer…
Europe’s leading cancer conference may be swimming in ADC data, but AstraZeneca remains convinced its in-house pipeline sets the pharma apart.
Tubulis’ next-generation ADC has…
Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.
GSK may be happy with the latest…
GSK may be happy with the latest readouts from two Hansoh-partnered ADCs, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data.
Cancer biotech Vivace Therapeutics…
Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant mesothelioma.
Xoma Royalty and Lava Therapeutics…
Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions for an acquisition inked back in August.